GlassScriptPhysician profile
James R Yates
NPI 1699769174
$1,571.13
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $364 · 2021: $432 · 2022: $325 · 2023: $21.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $623.36 | 2019-2022 | |
| Novo Nordisk INC | $217.32 | 2019-2022 | |
| Lilly USA, LLC | $142.91 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $128.22 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.16 | 2019-2022 | |
| Abbvie INC. | $73.29 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $63.42 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.84 | 2022 | |
| Dexcom, INC. | $37.09 | 2021-2023 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $31.73 | 2019-2021 | |
| Ucb, INC. | $27.77 | 2019 | |
| Pfizer INC. | $20.78 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.14 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.60 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.84 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $12.88 | 2022 | |
| Allergan, INC. | $12.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Yates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.